Dr. Vega is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
BIDMC/HMS - Neurosurgery
110 Francis St., Lowry Ste 3B
Boston, MA 02215Phone+1 617-632-7246Fax+1 617-632-0949- Is this information wrong?
Summary
- Dr. Rafael Vega is a board-certified neurosurgeon in Boston, MA and affiliated with Beth Israel Deaconess Medical Center, Harvard Medical School. He received his fellowship training at MD Anderson in Neurosurgical Oncology. He serves as Director of the Brain Tumor Center at BIDMC and is a Member of Dana-Farber/Harvard Cancer Center. He specializes in the treatment of malignant/benign brain tumors.
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Neurosurgical Oncology, 2018 - 2019
- Virginia Commonwealth University Health SystemResidency, Neurological Surgery, 2011 - 2018
- University of Virginia Medical CenterNeuro-Oncology Research, 2015 - 2016
- University of Illinois College of MedicineClass of 2011, MD
- Northwestern UniversityPhD, Chemistry of Life Processes, 2003 - 2007
- University of ColoradoBS, Chemistry, with High Distinction, 2000 - 2003
Certifications & Licensure
- MA State Medical License 2019 - 2025
- NH State Medical License 2024 - 2024
- American Board of Neurological Surgery Neurological Surgery
- The Society of Neurological SurgeonsCommittee on Advanced Subspecialty Training (CAST) in Neurosurgical Oncology
Awards, Honors, & Recognition
- Fellow of the Congress of Neurological Surgeons (FCNS) Congress of Neurological Surgeons, 2024
- Boston Magazine Top Doctor 2024
- Castle Connolly Top Doctor (Regional) 2023-2024
- Join now to see all
Clinical Trials
- Surgical Pembro +/- Olaparib w TMZ for rGBM Start of enrollment: 2022 Oct 21
Roles: Contact
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas Start of enrollment: 2022 Jun 20
Publications & Presentations
PubMed
- 12 citationsTranexamic Acid for Recurring Subdural Hematomas Following Surgical Evacuation: A Clinical Case Series.Joel M. Stary, Leslie Hutchins, Rafael A. Vega
Journal of Neurological Surgery. Part A, Central European Neurosurgery. 2016-06-14 - 1 citationsGrowth Analysis of Untreated Meningiomas under Observation.Charles F Opalak, Adam P Sima, Matthew Thomas Carr, Andrew Rock, Aravind Somasundaram
Journal of Neurological Surgery. Part A, Central European Neurosurgery. 2023-03-01 - 37 citationsEvaluation of glycerol-preserved bone allografts in cervical spine fusion: a prospective, randomized controlled trialR. Scott Graham, Brian Samsell, Allison Proffer, Mark A. Moore, Rafael A. Vega
Journal of Neurosurgery. Spine. 2015-01-01
Books/Book Chapters
Committees
- Co-Chair, CNS Journal Club Podcast 2019 - Present
Research History
- Principle Investigator, Surgical Neuro-Oncology Outcomes LaboratoryBeth Israel Deaconess Medical Center / Harvard Medical School2020 - Present
Professional Memberships
- Member
- Member
- Member
- Society of Neuro-OncologyMember
- North American Skull Base SocietyMember
Other Languages
- Spanish
Hospital Affiliations
- Beth Israel Deaconess Medical CenterBoston, Massachusetts
External Links
- DF/HCC Profilehttps://www.dfhcc.harvard.edu/insider/member-detail/member/rafael-a-vega-md-phd/
- BIDMC Brain Tumor Centerhttps://www.bidmc.org/centers-and-departments/cancer-center/cancer-center-programs-and-services/brain-tumor-program
- BIDMC Neurosurgeryhttps://www.bidmc.org/centers-and-departments/neurosurgery
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: